HLS Therapeutics (HLS) Stock Price, News & Analysis

Company Overview

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.

Key Stats

• Today's Range: C$4.09 to C$4.21
• 50-Day Range: C$3.60 to C$4.31
• 52-Week Range: C$3.56 to C$5.77
• Volume: 132,779 shs
• Average Volume: 28,801 shs
• Market Capitalization: C$126.52 million
• P/E Ratio: N/A
• Dividend Yield: 4.30%
• Price Target: C$8.00
• Consensus Rating: Strong Buy

HLS Therapeutics Stock Analysis - MarketRank™

HLS Therapeutics scored higher than 77% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Strong Buy

Consensus Rating

HLS Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

HLS Therapeutics has a consensus price target of C$8.00, representing about 94.6% upside from its current price of C$4.11.

Amount of Analyst Coverage

HLS Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of HLS Therapeutics is -15.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HLS Therapeutics is -15.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HLS Therapeutics has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HLS.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

HLS Therapeutics is a leading dividend payer. It pays a dividend yield of 4.30%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

HLS Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.92

News Sentiment

HLS Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for HLS Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of HLS Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net C$17,045.00 in company stock, which represents 0.0134% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, HLS Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$17,045.00 in company stock and sold C$0.00 in company stock.

Percentage Held by Insiders

0.37% of the stock of HLS Therapeutics is held by insiders.

Percentage Held by Institutions

6.14% of the stock of HLS Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/15/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: TSE:HLS
• CIK: N/A
• Web: www.hlstherapeutics.com
• Phone: 647-495-9000
• Fax: N/A
• Employees: 91
• Year Founded: N/A

Price Target and Rating

• Average Price Target for HLS Therapeutics: C$8.00
• High Price Target: C$8.00
• Low Price Target: C$8.00
• Potential Upside/Downside: +92.3%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): C($0.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$15.53 million
• Net Margins: -15.26%
• Pretax Margin: N/A
• Return on Equity: -14.39%
• Return on Assets: -2.89%

Debt

• Debt-to-Equity Ratio: 75.86
• Current Ratio: 1.05
• Quick Ratio: 1.01

Sales & Book Value

• Annual Sales: C$56.24 million
• Price / Sales: 2.29
• Cash Flow: C$0.27 per share
• Price / Cash Flow: 15.22
• Book Value: C$1.76 per share
• Price / Book: 2.36

Miscellaneous

• Outstanding Shares: 30,935,000
• Free Float: N/A
• Market Cap: C$128.69 million
• Optionable: Not Optionable
• Beta: -0.48